A new drug for people who have one of the worst forms of multiple sclerosis aims to make treatment much easier for patients. Ocrevus is a medicine commonly used to treat primary progressive MS ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

National Multiple Sclerosis Society: "FDA Approves Ocrevus™ (ocrelizumab) for People with Primary Progressive MS or Relapsing MS -- First Disease-Modifying Therapy for Primary Progressive MS ...

The quest to understand and slow disease progression in multiple sclerosis (MS) continued in 2024, with research revealing ...

Multiple Sclerosis Trust (UK): “Ocrevus.” MS Society (UK): “Targeting B cells to treat progressive MS.” Fiona Gupta, MD, neurologist and director of wellness and health, Icahn School of ...

She was diagnosed with secondary progressive multiple sclerosis in 2010 ... As the availability of Ocrevus Zunuvo continues to increase across the country, Josh Weber, UVA Health’s director ...

In September 2024, Roche, secured FDA approval for an injectable form of its blockbuster multiple sclerosis treatment, Ocrevus, reducing patient treatment time and potentially helping the company stay ...

Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and ...

New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Mapping cell types in MS lesions reveals unique tissue niches and interactions, offering insights into the molecular drivers ...